REFERENCES

• KasMJSerrettiAMarstonHQuantitative neurosymptomatics: Linking quantitative biology to neuropsychiatryNeurosci Biobehav Rev2019971230476505
   PubMed Web of Science ®Google Scholar
• PapassotiropoulosAde QuervainDJFFailed drug discovery in psychiatry: time for human genome-guided solutionsTrends Cogn Sci201519418318710.1016/j.tics.2015.
02.002 25727774
   PubMed Web of Science ®Google Scholar
• TargumSDPollackMHFavaMRedefining affective disorders: relevance for drug developmentCNS Neurosci Ther20081412918482094
   PubMed Web of Science ®Google Scholar
• NicholsonJRSommerBThe research domain criteria framework in drug discovery for neuropsychiatric diseases: focus on negative valenceBrain Neurosci Adv2018211010.1177/
2398212818804030 31742235
   PubMedGoogle Scholar
• MeyersOIThe role of DSM in the EMA and FDA authorization process for psychiatric drugsValue Health2013167A61310.1016/j.jval.2013.08.1767
   Web of Science ®Google Scholar
• KupferDThe DSM-5 - an interview with David KupferBMC Med20131120324229066
   PubMed Web of Science ®Google Scholar
• KendellRJablenskyADistinguishing between the validity and utility of psychiatric diagnosesAm J Psychiatry2003160141212505793
   PubMed Web of Science ®Google Scholar
• ClarkeDENarrowWERegierDAet alDSM-5 field trials in the United States and Canada, Part I: study design, sampling strategy, implementation, and analytic approachesAm J Psychiatry20131701435823111546
   PubMed Web of Science ®Google Scholar
• MajM“Psychiatric comorbidity”: an artefact of current diagnostic systems?Br J Psychiatry200518618218415738496
   PubMed Web of Science ®Google Scholar
• SmollerJWAndreassenOAEdenbergHJFaraoneSVGlattSJKendlerKSPsychiatric genetics and the structure of psychopathologyMol Psychiatry20192440942010.1038/
s41380-017-0010-4 29317742
   PubMed Web of Science ®Google Scholar
• DeanCEPsychopharmacology: A house dividedProg Neuropsychopharmacol Biol Psychiatry201135111020828593
   PubMed Web of Science ®Google Scholar
• MoncrieffJThe Bitterest Pills: the Troubling Story of Antipsychotic Drugs2013 Houndmills, UK Palgrave Macmillan
   Google Scholar
• DavisKLKahnRSKoGDavidsonMDopamine in schizophrenia: a review and reconceptualizationAm J Psychiatry199114811147414861681750
   PubMed Web of Science ®Google Scholar
• HirschfeldRMHistory and evolution of the monoamine hypothesis of depressionJ Clin Psychiatry200061Suppl 646
   PubMed Web of Science ®Google Scholar
• ShorterEWhat Psychiatry Left Out of the DSM-5: Historical Mental Disorders Today2015 New York, NY Routledge
   Google Scholar
• MontgomerySAre the ICD-10 or DSM-5 diagnostic systems able to define those who will benefit from treatment for depression?CNS Spectrums201621428328810.1017/S1092852916000389 27418397
   PubMed Web of Science ®Google Scholar
• MoritzSGawędaŁHeinzAGallinatJFour reasons why early detection centers for psychosis should be renamed and their treatment targets reconsidered: we should not catastrophize a future we can neither reliably predict nor changePsychol Med201949132134214010.1017/S0033291719001740 31337458
   PubMed Web of Science ®Google Scholar
• MoncrieffJResearch on a ‘drug-centred’ approach to psychiatric drug treatment: assessing the impact of mental and behavioural alterations produced by psychiatric drugsEpidemiol Psychiatr Sci201827213314010.1017/S2045796017000555 29022518
   PubMed Web of Science ®Google Scholar
• WickJYThe history of benzodiazepinesConsult Pharm201328953854810.4140/TCP.n.2013.538 24007886
   PubMedGoogle Scholar
• MoultonCDKoychevIThe effect of penicillin therapy on cognitive outcomes in neurosyphilis: a systematic review of the literatureGen Hosp Psychiatry2015371495210.1016/
j.genhosppsych.2014.10.008 25468254
   PubMed Web of Science ®Google Scholar
• RazAHarrisCSPlacebo Talks - Modern perspectives on Placebos in Society2016 Oxford, UK Oxford University Press
   Google Scholar
• TomeMBIsaacMTA regulatory view on novel methodologies and context of use of biomarkersNeurosci Biobehav Rev201997949510.1016/j.neubiorev.2018.09.015 30261197
   PubMed Web of Science ®Google Scholar
• WeiserMReichenbergARabinowitzJet alCognitive performance of male adolescents is lower than controls across psychiatric disorders: a population-based studyActa Psychiatr Scand2004110647147515521833
   PubMed Web of Science ®Google Scholar
• ReichenbergAVelthorstEDavidsonMCognitive impairment and psychosis in schizophrenia: independent or linked conditions?World Psychiatry201918216216310.1002/wps.20644 31059615
   PubMed Web of Science ®Google Scholar
• DavidsonMCognitive impairment as a diagnostic criterion and treatment target in schizophreniaWorld Psychiatry201918217117210.1002/
wps.20651 31059612
   PubMed Web of Science ®Google Scholar
• RichardsALPardiñasAFFrizzatiAet alThe relationship between polygenic risk scores and cognition in schizophreniaSchizophr Bull201946233634410.1093/schbul/sbz061
   Web of Science ®Google Scholar
• MoncrieffJSteingardSA critical analysis of recent data on the long-term outcome of antipsychotic treatmentPsychol Med201949575075310.1017/S0033291718003811
   PubMed Web of Science ®Google Scholar
• KasMJPenninxBSommerBSerrettiAArangoCMarstonHA quantitative approach to neuropsychiatry: The why and the howNeurosci Biobehav Rev2019973910.1016/
j.neubiorev.2017.12.008 29246661
   PubMed Web of Science ®Google Scholar
• CaeiroLFerroJMCostaJApathy secondary to stroke: a systematic review and meta- analysisCerebrovasc Dis2013351233910.1159/
000346076
   PubMed Web of Science ®Google Scholar
• StarksteinSEPahissaJApathy following traumatic brain injuryPsychiatr Clin N Am201437110311210.1016/j.psc.2013.10.002
   PubMed Web of Science ®Google Scholar
• BarchDMPagliaccioDLukingKMechanisms underlying motivational deficits in psychopathology: similarities and differences in depression and schizophreniaCurr Top Behav Neurosci20162741144910.1007/7854_2015_376 26026289
   PubMedGoogle Scholar
• HusainMRoiserJPNeuroscience of apathy and anhedonia: a transdiagnostic approachNat Rev Neurosci20181947048429946157
   PubMed Web of Science ®Google Scholar
• StraussGPCohenASA Transdiagnostic review of negative symptom phenomenology and etiologySchizophrenia Bull201743471272910.1093/schbul/sbx066
   PubMed Web of Science ®Google Scholar
• SamiMBFaruquiRThe effectiveness of dopamine agonists for treatment of neuropsychiatric symptoms post brain injury and strokeActa Neuropsychiatr201527631732610.1017/neu.2015.17 25850757
   PubMed Web of Science ®Google Scholar
• RosenbergPBLanctôtKLDryeLTet alSafety and efficacy of methylphenidate for apathy in Alzheimer’s disease: a randomized, placebo-controlled trialJ Clin Psychiatry201374881081610.4088/JCP.12m08099 24021498
   PubMed Web of Science ®Google Scholar
• CorcoranCWongMLO’KeaneVBupropion in the management of apathyJ Psychopharmacol200418113313515107198
   PubMed Web of Science ®Google Scholar
• RuthirakuhanMTHerrmannNAbrahamEHChanSLanctôtKLPharmacological interventions for apathy in Alzheimer’s diseaseCochrane Database Syst Rev20185CD01219710.1002/
14651858.CD012197.pub2 29727467
   PubMedGoogle Scholar
• SchererRWDryeLMintzerJet alThe Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trialTrials2018194610.1186/s13063-017-
2406-5 29347996
   PubMedGoogle Scholar
• DavidsonMSaoudJStanerCet alEfficacy and safety of MIN-101: a 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophreniaAm J Psychiatry2017174121195120210.1176/appi.ajp.
2017.17010122 28750582
   PubMed Web of Science ®Google Scholar
• RabinowitzJBadescuSPalamarchukPet alPersonal and social adjustment effects of roluperidone in patients with schizophrenia and negative symptoms: Results from an exploratory outcome of a randomized placebo-controlled trialSchizophr Res201921110310410.1016/j.schres.2019.07.029 31375316
   PubMed Web of Science ®Google Scholar
• NemeroffCBWeinbergerDRutterMet alDSM-5: a collection of psychiatrist views on the changes, controversies, and future directionsBMC Med20131120210.1186/1741-7015-11-202 24229007
   PubMed Web of Science ®Google Scholar
• KendlerKSFrom many to one to many—the search for causes of psychiatric illnessJAMA Psychiatry201976101085109110.1001/jamapsychiatry.2019.1200
   PubMed Web of Science ®Google Scholar